The New Zealand-based company is gearing up for industrial production of pharmaceutical-grade algal omega-3.
The algae omega-3 market appears to be spreading as fast as the stuff grows on my fish tank.
New Zealand-based Photonz Corp. (Auckland) last week announced that it is staged to begin production of a pharmaceutical-grade algal omega-3 eicosapentaenoic acid (EPA). The ingredient will be marketed for pharmaceutical applications relating to cardiovascular disease.
The company is employing supercritical extraction technology from Separex S.A. (Champigneulles, France) to produce the concentrated EPA from Photonz’s algae strains.
“Separex has extensive experience in working with this type of oil, currently derived from non-algal sources, such as fish,” says Photonz chief executive Greg Moss-Smith. “That experience is of considerable importance because, to meet the needs of the cardiovascular disease market, our product will have to be identical to fish-derived product.”
Separex is expected to reach industrial scale production of the ingredient in late 2011, before the technology is transferred to a contract manufacturer.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.